Kiora Pharmaceuticals and Théa Open Innovation Have Entered into a Development and Commercialization Agreement of ~ $301M
Shots:
- Under the collaboration, Kiora is entitled to receive $16M upfront payment, ~$285M milestones based on clinical, regulatory & commercial development, up to low 20% tiered royalties on net sales as well as reimbursement for KIO-301 R&D expenses while TOI obtains exclusive global (excl. Asia) development and commercialization rights of KIO-301 to treat degenerative retinal diseases
- Kiora will be responsible for the P-II trial and TOI will be responsible for the P-III study, regional marketing approvals plus all the commercial activities incl. sales, marketing and market access
- Furthermore, the agreement will cover ophthalmic indications incl. retinitis pigmentosa across the globe excl. China, Japan, and some Asian regions
Ref: Kiora Pharmaceuticals | Image: Théa Open Innovation
Related News:- Théa Open Innovation Signs a License Agreement with Galimedix to Develop and Commercialize GAL-101 for Ophthalmic Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
